Abstract
Follicular lymphoma is essentially a disease of the elderly, and the aging of the population in developed countries will increase patient numbers in coming years. Significant achievements have been made for treatment, but better understanding of the disease and major progress in biology now facilitate the development of many new drugs, which may have improved toxicity profiles making them appropriate for treatment of older adults. However, the increasing number of treatment possibilities, can also increase the toxicity risks, and unexpected toxicities specific to older adults may be encountered. Consequently, specific studies of older patients should be considered, using appropriate evaluation tools such as comprehensive geriatric assessment. This review will described the development of these new drugs, in the context of the treatment of older-adults with follicular lymphoma.
Keywords: Aged, elderly, Follicular lymphoma, frailty, new drugs, old, targeted therapies.
Anti-Cancer Agents in Medicinal Chemistry
Title:New Drugs for Follicular Lymphoma in Older Adults
Volume: 14 Issue: 5
Author(s): Anna Schmitt and Pierre Soubeyran
Affiliation:
Keywords: Aged, elderly, Follicular lymphoma, frailty, new drugs, old, targeted therapies.
Abstract: Follicular lymphoma is essentially a disease of the elderly, and the aging of the population in developed countries will increase patient numbers in coming years. Significant achievements have been made for treatment, but better understanding of the disease and major progress in biology now facilitate the development of many new drugs, which may have improved toxicity profiles making them appropriate for treatment of older adults. However, the increasing number of treatment possibilities, can also increase the toxicity risks, and unexpected toxicities specific to older adults may be encountered. Consequently, specific studies of older patients should be considered, using appropriate evaluation tools such as comprehensive geriatric assessment. This review will described the development of these new drugs, in the context of the treatment of older-adults with follicular lymphoma.
Export Options
About this article
Cite this article as:
Schmitt Anna and Soubeyran Pierre, New Drugs for Follicular Lymphoma in Older Adults, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (5) . https://dx.doi.org/10.2174/1871523013666140416100814
DOI https://dx.doi.org/10.2174/1871523013666140416100814 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Pharmaceutical Design Searching Drug-Like Anti-cancer Compound(s) Based on G-Quadruplex Ligands
Current Pharmaceutical Design Development and biological studies of <sup>177</sup>Lu-DOTA-rituximab for the treatment of Non-Hodgkin’s lymphoma
Current Radiopharmaceuticals Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dellAdulto) Multiple Myeloma Working Party Perspective
Current Drug Targets Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry MicroRNA-21 as a Novel Therapeutic Target
Current Cancer Therapy Reviews Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Epidemiology and Pathology of Malignant Mesothelioma
Current Respiratory Medicine Reviews Vitamins for Cancer Prevention and Treatment: An Insight
Current Molecular Medicine Biologically Active Selenophenes and Benzo[b]selenophenes
Current Organic Synthesis Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Glycosides from Medicinal Plants as Potential Anticancer Agents: Emerging Trends Towards Future Drugs
Current Medicinal Chemistry Design, Synthesis, and Anticancer Potential of the Enzyme (PARP-1) Inhibitor with Computational Studies of New Triazole, Thiazolidinone, - Thieno [2, 3-d] Pyrimidinones
Letters in Drug Design & Discovery Antagonists of CCR4 as Immunomodulatory Agents
Current Topics in Medicinal Chemistry Zevalin™: 90Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin ’ s Lymphoma
Current Pharmaceutical Biotechnology Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Reviews on Recent Clinical Trials Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design